Dec 10 (Reuters) - Astria Therapeutics ATXS.O:
ASTRIA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR STAR-0310, A MONOCLONAL ANTIBODY OX40 ANTAGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
ASTRIA THERAPEUTICS INC: PHASE 1A TRIAL OF STAR-0310 IN HEALTHY VOLUNTEERS EXPECTED TO INITIATE IN Q1 2025
ASTRIA THERAPEUTICS INC: EARLY PROOF-OF-CONCEPT RESULTS EXPECTED IN Q3 2025
Source text: ID:nBw3gg0WFa
Further company coverage: ATXS.O
((Reuters.Briefs@thomsonreuters.com;))